Please use this identifier to cite or link to this item:
|Title:||Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients|
|Authors:||Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.|
Hacımustafaoğlu, Mustafa Kemal
|Citation:||Çelebi, S. vd. (2010). "Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients". Pediatrics International, 52(3), 410-414.|
|Abstract:||Aim: The aim of the present study was to assess the efficacy and safety of colistimethate sodium therapy in multidrug-resistant nosocomial infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii in neonates and children. Methods: Pediatric patients hospitalized at the Uludag University Hospital who had nosocomial infections caused by multidrug-resistant P. aeruginosa or A. baumannii, were enrolled in the study. Colistimethate sodium at a dosage of 50-75 x 103 U/kg per day was given i.v. divided into three doses. Results: Fifteen patients received 17 courses of colistimethate sodium for the following infections: ventilator-associated pneumonia (n = 14), catheter-related sepsis (n = 1) and skin and soft-tissue infection (n = 2). The mean age of patients was 53.2 + 74.7 months (range, 8 days-15 years) and 60% were male. Mortality was 26.6%. Conclusion: Colistimethate sodium appears to be safe and effective for the treatment of severe infections caused by multidrug-resistant P. aeruginosa or A. baumannii in pediatric patients.|
|Appears in Collections:||Scopus|
Web of Science
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.